In its second year, the Innovators in Science Award recognizes research excellence in Regenerative Medicine. Shruti Naik, PhD (Damon Runyon Fellow '14-'17 and Damon Runyon-Dale F. Frey Breakthrough Scientist '17-'19) of New York University, received the Early-Career Scientist Award with a $200,000 grant.

Damon Runyon scientists recently shared some of the cutting-edge cancer therapies that are saving lives at an event sponsored by the Young Presidents’ Organization in New York City. Jedd D. Wolchok, MD, PhD, discussed immunotherapy for melanoma—these drugs harness a patient’s immune system to find and kill cancer cells. Christopher E. Barbieri, MD, PhD, presented his research using therapy to specifically target the damage in prostrate cells that causes cancer. Today, these two approaches play a critical role in treating cancer and providing hope for many patients.

By Lorraine W. Egan, Outgoing President and CEO of Damon Runyon Cancer Research Foundation

Earlier this month, I attended my last meeting of the Damon Runyon Fellowship Award Committee before I retire. Damon Runyon conducts peer review at the highest level with the most respected scientific leaders reviewing the proposals of our applicants to decide if they merit funding.This meeting reaffirmed my strong belief that rigorous peer review works in choosing the best scientists to fund.

Carla Koehler, PhD (Damon Runyon Fellow '95-'98 and Scholar '99-'02) of the University of California, Los Angeles, was named an American Association for the Advancement of Science Fellow for significant contributions in characterizing mechanisms of protein and RNA transport in the mitochondria. The tradition of AAAS Fellows dates to 1874 and comprises an illustrious group of scientists, including many Nobel Laureates.

Nicholas Arpaia, PhD (Damon Runyon Fellow '12-'16) of Columbia University, and his colleague received the $500,000 prize to support research on designing probiotic bacterial strains that find and attack lung cancer. The Young Innovator Team Awards were established in 2014 to encourage out-of-the-box thinking and foster leadership skills among young researchers, instilling confidence in them to drive breakthrough lung cancer research using a collaborative, cross-institutional approach. 

The Damon Runyon-Jake Wetchler Award for Pediatric Innovation is given annually to a third-year Damon Runyon Fellow whose research has the greatest potential to impact the prevention, diagnosis or treatment of pediatric cancer. In its third year, Challice L. Bonifant, MD, PhD, received this special award at the annual Fellows' Retreat.

Approximately 450 supporters took part in Runyon Up, the first fundraising stair climb held at the newly opened Salesforce Tower in San Francisco on October 21. Climbers faced a unique vertical challenge in the 61-story building, the tallest in San Francisco, and were rewarded with breathtaking views from the top.

Patients with metastatic breast cancer—when the tumor has spread to other organs in the body—face a terminal prognosis and toxic treatments. There is an urgent need for new ways to treat drug metastatic and resistant stages of the disease. Sarat Chandarlapaty, MD, PhD (Clinical Investigator ’12-’17), and colleagues, have developed a novel class of drugs that may help these patients by potentially stopping or even destroying breast cancer tumors.

Two Damon Runyon alumni were elected to the National Academy of Medicine. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

By Yung S. Lie, PhD, Incoming President and Chief Executive Officer of the Damon Runyon Cancer Research Foundation

Damon Runyon congratulates the recipients of the 2018 Nobel Prize in Physiology or Medicine, James P. Allison and Tasuku Honjo, for their discovery that certain proteins act as “brakes” on the immune system, limiting its ability to attack cancer cells. Drugs called checkpoint inhibitors have since been developed to take these brakes off, freeing the immune cells to fight cancer and save countless lives. The field of checkpoint inhibition, as well as the entire field of immunotherapy (harnessing the immune system to recognize and attack cancer cells), has exponentially grown in importance due to the contributions of a community of many scientists. We are proud to have supported several Damon Runyon scientists, who have made critical discoveries that have helped bring this new class of drugs to patients.